Stocks:
5,168
ETFs:
2,288
Exchanges:
11
Market Cap:
$64.79T
24h Vol:
$16.23B
Dominance:
MSFT:4.76%
Stocklytics Platform
Asset logo  SLNO
Soleno Therapeutics
SLNO
62 / 100
High Growth
$45.70arrow_drop_up1.08%$0.49

Performance History

Stocklytics logo
Key Stats
Open$45.20
Prev. Close$45.21
EPS-2.36
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$1.63B
PE Ratio-
LOWHIGH
Day Range44.60
45.92
52 Week Range3.69
53.82
Ratios
P/B Ratio7.65
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %-62.00%
EBITDA Margin %-
ROE %-46.45%
EPS-2.36

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$787.02
24H (%)arrow_drop_up3.01%
24H ($)$23.04
MARKET CAP$722.30B
PRICE$517.54
24H (%)arrow_drop_up0.71%
24H ($)$3.66
MARKET CAP$471.98B
PRICE$152.67
24H (%)arrow_drop_up0.85%
24H ($)$1.28
MARKET CAP$360.78B
PRICE$131.73
24H (%)arrow_drop_up2.38%
24H ($)$3.06
MARKET CAP$329.41B

About Soleno Therapeutics (SLNO)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Anish Bhatnagar M.D.
Headquarters
Redwood City
Employees
25
Exchange
NASDAQ
add Soleno Therapeutics  to watchlist

Keep an eye on Soleno Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Soleno Therapeutics 's (SLNO) price per share?

The current price per share for Soleno Therapeutics (SLNO) is $45.21. The stock has seen a price change of $1.71 recently, indicating a 3.93% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Soleno Therapeutics (SLNO)?

For Soleno Therapeutics (SLNO), the 52-week high is $53.82, which is 19.04% from the current price. The 52-week low is $3.69, the current price is 1.13K% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Soleno Therapeutics (SLNO) a growth stock?

Soleno Therapeutics (SLNO) has shown an average price growth of 0.41% over the past three years. It has received a score of 98 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Soleno Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Soleno Therapeutics (SLNO) stock price performance year to date (YTD)?

As of the latest data, Soleno Therapeutics (SLNO) has a year-to-date price change of 19.13%. Over the past month, the stock has experienced a price change of 17.37%. Over the last three months, the change has been -4.07%. Over the past six months, the figure is 100.13%. Looking at a longer horizon, the five-year price change stands at 54.56%.

help
Is Soleno Therapeutics (SLNO) a profitable company?

Soleno Therapeutics (SLNO) has a net income of -$38.99M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$38.67M. Furthermore, the EBITDA is -$36.71M.

help
What is the market capitalization of Soleno Therapeutics (SLNO)?

Soleno Therapeutics (SLNO) has a market capitalization of $1.64B. The average daily trading volume is 492.8K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level